| Product Name | GS-441524 |
| Expiry Date | 1 Year From The Date Of Manufacture |
| Storage Condition | Room Temperature |
| CAS | 1191237-69-0 |
| Function | Treatment For Cat FIP |
| Dosage Form | Injection |
| Country of Manufacture | China |
| Packaging | 6ml/vial, 8ml/vial, 10ml/vial |
| Strength | 20mg and 30mg |
GS-441524 Injectable is an investigational antiviral medication that has attracted significant interest, particularly among veterinarians. It belongs to the class of nucleotide analogs and was initially developed by Gilead Sciences as a foundational compound for remdesivir, an antiviral drug utilized in treating COVID-19 in humans. GS-441524 has gained recognition for its effectiveness in combating feline infectious peritonitis (FIP), a lethal viral illness caused by a coronavirus in cats.
GS-441524 has demonstrated substantial efficacy in treating FIP, a disease that was once considered untreatable in felines. The medication functions by blocking the replication of the coronavirus responsible for FIP.
While GS-441524 is chemically similar to remdesivir, it has not received approval for use in humans. Nonetheless, its antiviral capabilities have sparked interest for potential use in treating other viral infections.
The injectable form of GS-441524 is usually given subcutaneously (under the skin) to cats diagnosed with FIP. This method of administration has resulted in a high rate of success in curing the condition.
"FIP" refers to Feline Infectious Peritonitis (FIP), which is a viral disease caused by certain strains of feline coronavirus (FCoV).
Cause: FIP is caused by a mutation of the feline coronavirus (FCoV). Most cats with FCoV do not develop FIP, but in some cases, the virus mutates into a form that causes FIP.
Transmission: FCoV is commonly spread through feces and oral-fecal transmission, often in multi-cat environments such as shelters or catteries. Once a cat is infected with FCoV, it may develop either a mild, self-limiting form of the disease or progress to FIP.
Forms of FIP: FIP presents in two main forms: effusive (wet) and non-effusive (dry). Effusive FIP involves the accumulation of fluid in body cavities, such as the abdomen or chest. Non-effusive FIP is characterized by granulomatous lesions in various organs.
Symptoms: Symptoms of FIP can vary widely and may include fever, weight loss, lethargy, jaundice, difficulty breathing, and fluid accumulation in the abdomen or chest in the case of effusive FIP. Neurological symptoms can also occur in some cases.
Diagnosis: FIP can be challenging to diagnose definitively, as clinical signs and laboratory tests are often non-specific. Diagnosis may involve a combination of clinical evaluation, laboratory tests (such as bloodwork, imaging, and fluid analysis), and sometimes histopathology.
Prevention: Prevention of FIP focuses on reducing exposure to FCoV. This includes minimizing stress, maintaining good hygiene and sanitation practices, and reducing overcrowding in multi-cat environments. Vaccines for FIP are available, but their efficacy remains controversial.
GS-441524 is an antiviral drug that has shown promise in the treatment of feline infectious peritonitis (FIP), a viral disease caused by certain strains of feline coronavirus. As of my last update, GS-441524 is primarily used off-label in cats with FIP.
The dosage of GS-441524 injection for cats with FIP can vary depending on factors such as the cat's weight, the severity of the disease, and the veterinarian's assessment. Dosage regimens may also vary based on individual response and the specific formulation of GS-441524 being used.
Recommended dosage:
FIP(Wet): 0.3ml/kg * body weight kg + 0.1ml residue
FIP (Dry): 0.4ml/kg * body weight kg + 0.1ml residue
Eye / nerve entry: 0.5ml/kg * body weight kg + 0.1ml residue
Recurrence: 0.6 ml / kg * body weight kg + 0.1ml residue
